Guclu, M. Et Al. 2018. Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus. ENDOCRINE CONNECTIONS , vol.7, no.1 , 193-198.

Guclu, M., Kiyici, S., Gul, Z., & ÇAVUN, S., (2018). Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus. ENDOCRINE CONNECTIONS , vol.7, no.1, 193-198.

Guclu, Metin Et Al. "Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus," ENDOCRINE CONNECTIONS , vol.7, no.1, 193-198, 2018

Guclu, Metin Et Al. "Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus." ENDOCRINE CONNECTIONS , vol.7, no.1, pp.193-198, 2018

Guclu, M. Et Al. (2018) . "Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus." ENDOCRINE CONNECTIONS , vol.7, no.1, pp.193-198.

@article{article, author={Metin Guclu Et Al. }, title={Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus}, journal={ENDOCRINE CONNECTIONS}, year=2018, pages={193-198} }